SCHEMBL5074162

SCHEMBL5074162

FC(F)Oc1ccc(CNCC2CCCCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 2/20 0.52
▸ HDAC3 O15379 1/20 0.48
▸ HDAC4 P56524 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC5 Q9UQL6 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MAPT P10636 2/20 0.46
▸ HTT P42858 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ PDE4A P27815 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ MDM2 Q00987 1/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29336471 0.80 HTT (0.62) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL8041968 0.78 SMN1; SMN2 (0.65) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL8826390 0.78 HTT (0.58) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL9625968 0.77 HRH3 (0.57) HDAC1ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL3861590 0.76 HDAC6 (0.62) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL8493195 0.76 ALDH1A1 (0.56) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL18088394 0.74 RAB9A (0.60) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL7248082 0.74 HDAC6 (0.60) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL14965788 0.74 ALDH1A1 (0.54) ALDH1A1TSHRMAPTHTTSMN1; SMN2
SCHEMBL3085761 0.74 HDAC6 (0.60) HDAC6HDAC3HDAC4HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 — — EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 — — EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 — — WO disclosed
Send feedback